FN1 and breast cancer: Noninvasive biomarkers have a clinical potential in the management of solid malignancies, such as prostate, ovarian, and breast cancer (7), for instance fibronectin (FN) which is present on the surface of extra vesicles released from human breast cancer cell lines, was considered as a potential biomarker candidate (32).